The molecular nucleic acid testing transfusion medicine market reached USD 1053.61 million in 2026. This growth is driven by the rising prevalence of genetic disorders, advances in molecular diagnostics, and increasing investments. These trends were analyzed by our Senior Research Analyst, Deepa Pandey, to curate this report. This report benefits several stakeholders, including major biotech giants, healthcare conglomerates, large-scale commercial reference laboratories, and medical device manufacturers.